Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Aug 8, 2024
-- Generated $41.5 million in net revenue from sales of LUMRYZ™ --
-- More than 1,900 patients on LUMRYZ as of June 30th --
Read more at globenewswire.com
